GSK's Arzerra gets preliminary NICE nod; Obesity drug demand on the rise;

@FiercePharma: Top-read on FP Monday: AstraZeneca seals the deal for Almirall's respiratory meds. Article | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: The revamp continues at Takeda, as does its financial struggles. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Report: Orphan drugs to nab 19% of drug sales by 2020--if payers don't balk, that is. Article | Follow @CarlyHFierce

> The U.K.'s cost watchdog has issued preliminary draft guidance proposing recommendation of GlaxoSmithKline's ($GSK) Arzerra with chlorambucil for untreated chronic lymphocytic leukaemia (CLL). More

> After a pair of new contenders hit the market last month, demand for obesity drugs is on the rise. Report

> China's WuXi PharmaTech is on the hunt for Israeli investments. Report

> The World Health Organization (WHO) has recommended overdose-fighter naloxone to prevent 20,000 deaths in U.S. More

Medical Device News

@FierceMedDev: ReShape finally reveals pivotal obesity data ahead of FDA review. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger. Article | Follow @VarunSaxena2

@EmilyWFierce: New medical imaging device with scanner the size of an iPhone uses ultrasound chip to create 3-D images in real time. Story from MIT Technology Review | Follow @EmilyWFierce

> ReShape finally reveals pivotal obesity data ahead of FDA review. Story

> Blood loss app developer Gauss Surgical raises $1.5M in equity sale. Article

Biotech News

@FierceBiotech: AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal. Article | Follow @FierceBiotech

@JohnCFierce: Joined at the hip. RT @bradloncar: Len Schleifer mentioned Viehbacher axing. he's meeting with Weinberg soon, $REGN very committed to $SNY. | Follow @JohnCFierce

@DamianFierce: I've been off Twitter for a minute. Has anyone called for a $REGN breakup yet? | Follow @DamianFierce

@EmilyMFierce: ICYMI from FierceMedicalDevices: Boston Scientific faces first two federal trials for transvaginal mesh devices. Story | Follow @EmilyMFierce

> Astellas sinks deeper roots into Cambridge's hot R&D field with $1.2B discovery pact. Article

> Rand tallies a whopping $44B in biosimilar drug savings. Item

> Novo Nordisk builds blockbuster case with promising PhIII obesity data. Report

Biotech Research News

> Three-drug combo kills Ewing sarcoma in mice. More

> Potential target for triple-negative breast cancer found. Story

> 3D stomach tissue grown from human stem cells. Item

> Mouse model shows genetics plays role in Ebola severity. Article

> Drug combo causes lung cancer cells to self-destruct. More

Pharma Manufacturing News

> GSK gets go-ahead for expansion at plant in Scotland. Item

> Forest recalls another 90,000-plus bottles of Bystolic. Report

> Chinese company takes over Boehringer U.S. plant as German drugmaker expands in China. More

> Chairman says Wockhardt has no plans to sell. Story

> Novartis cuts more jobs at U.S. consumer plant ahead of handing it off to GSK. Article

And Finally... Two-thirds of U.K. general practitioners are refusing to comply with controversial NHS advice to prescribe statins to millions more adults, according to polls. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.